Keswani Sanjay Chandru 4

4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 17, 2026

Neurocrine (NBIX) CMO Sanjay Keswani Receives Equity Award

What Happened

Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences (NBIX), was granted equity awards on Feb 13, 2026. The filing shows an option award covering 35,827 shares (derivative security) and 6,285 restricted stock units (RSUs). Both items were reported as awards/acquisitions at $0.00 per share (no cash exchanged at grant).

Key Details

Transaction date: February 13, 2026; Form 4 filed February 17, 2026.
Grants reported:
- 35,827-share option (derivative) — reported as acquired at $0.00. (Footnote F1: vests 1/48th on March 13, 2026, then 1/48th monthly thereafter.)
- 6,285 RSUs — reported as acquired at $0.00. (Footnotes F2/F3: each RSU converts to one share; RSUs vest 25% annually on Feb 13 of 2027, 2028, 2029, and 2030.)
Shares owned after transaction: not specified in the provided summary of the filing.
Filing timeliness: Form 4 was filed four days after the grant date (filed Feb 17 for Feb 13 transaction). Check the SEC filing for any tardiness designation.

Context

These are compensation awards (an option grant plus time‑based RSUs), common for senior executives; they are not open‑market purchases or sales and do not represent an immediate cash transaction. The option vests monthly starting in March 2026 (1/48th each month), while the RSUs vest annually over four years (25% per year).

Form 4

Period: 2026-02-13

Chief Medical Officer

Transactions

Award
Stock Option
[F1]
2026-02-13+35,827→ 35,827 total
Exercise: $124.12Exp: 2036-02-13→ Common Stock (35,827 underlying)
Award
Restricted Stock Unit
[F2][F3]
2026-02-13+6,285→ 6,285 total
→ Common Stock (6,285 underlying)

Footnotes (3)

[F1]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
[F3]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

Signature

/s/ Darin Lippoldt, Attorney-in-Fact|2026-02-17

1 file